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In February 2018, the Recommended Immunization Schedule for Adults Aged 19 Years or Older, United 
States, 2018 became effective, as recommended by the Advisory Committee on Immunization Practices 
(ACIP) and approved by the Centers for Disease Control and Prevention (CDC). The adult immunization 
schedule was also approved by the American College of Physicians, the American Academy of Family 
Physicians, the American College of Obstetricians and Gynecologists, and the American College of 
Nurse-Midwives.
CDC announced the availability of the 2018 adult immunization schedule in the Morbidity and Mortality 
Weekly Report (MMWR).1 The schedule is published in its entirety in the Annals of Internal Medicine.2
The adult immunization schedule consists of figures that summarize routinely recommended vaccines 
for adults by age groups and medical conditions and other indications, footnotes for the figures, and 
a table of vaccine contraindications and precautions. Note the following when reviewing the adult 
immunization schedule:
• The figures in the adult immunization schedule should be reviewed with the accompanying 
footnotes.
• The figures and footnotes display indications for which vaccines, if not previously administered, 
should be administered unless noted otherwise.
• The table of contraindications and precautions identifies populations and situations for which 
vaccines should not be used or should be used with caution.
• When indicated, administer recommended vaccines to adults whose vaccination history is 
incomplete or unknown.
• Increased interval between doses of a multidose vaccine series does not diminish vaccine 
effectiveness; it is not necessary to restart the vaccine series or add doses to the series because of 
an extended interval between doses.
• Combination vaccines may be used when any component of the combination is indicated and 
when the other components of the combination are not contraindicated.
• The use of trade names in the adult immunization schedule is for identification purposes only and 
does not imply endorsement by the ACIP or CDC.
Special populations that need additional considerations include:
• Pregnant women. Pregnant women should receive the tetanus, diphtheria, and acellular pertussis 
vaccine (Tdap) during pregnancy and the influenza vaccine during or before pregnancy. Live 
vaccines (e.g., measles, mumps, and rubella vaccine [MMR]) are contraindicated. 
• Asplenia. Adults with asplenia have specific vaccination recommendations because of their 
increased risk for infection by encapsulated bacteria. Anatomical or functional asplenia 
includes congenital or acquired asplenia, splenic dysfunction, sickle cell disease and other 
hemoglobinopathies, and splenectomy.
• Immunocompromising conditions. Adults with immunosuppression should generally avoid 
live vaccines. Inactivated vaccines (e.g., pneumococcal vaccines) are generally acceptable. 
High-level immunosuppression includes HIV infection with a CD4 cell count <200 cells/μL, 
receipt of daily corticosteroid therapy with ≥20 mg of prednisone or equivalent for ≥14 days, 
primary immunodeficiency disorder (e.g., severe combined immunodeficiency or complement 
component deficiency), and receipt of cancer chemotherapy. Other immunocompromising 
conditions and immunosuppressive medications to consider when vaccinating adults can 
be found in IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.3 
Additional information on vaccinating immunocompromised adults is in General Best Practice 
Guidelines for Immunization.4
Additional resources for health care providers include:
• Details on vaccines recommended for adults and complete ACIP statements at www.cdc.gov/
vaccines/hcp/acip-recs/index.html
• Vaccine Information Statements that explain benefits and risks of vaccines at www.cdc.gov/
vaccines/hcp/vis/index.html
• Information and resources on vaccinating pregnant women at www.cdc.gov/vaccines/adults/rec-
vac/pregnant.html
• Information on travel vaccine requirements and recommendations at www.cdc.gov/travel/
destinations/list
• CDC Vaccine Schedules App for immunization service providers to download at www.cdc.gov/
vaccines/schedules/hcp/schedule-app.html
• Adult Vaccination Quiz for self-assessment of vaccination needs based on age, health conditions, 
and other indications at www2.cdc.gov/nip/adultimmsched/default.asp 
• Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger at 
www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html 
Report suspected cases of reportable vaccine-preventable diseases to the local or state health 
department, and report all clinically significant postvaccination events to the Vaccine Adverse Event 
Reporting System at www.vaers.hhs.gov or by telephone, 800-822-7967. All vaccines included in the 
adult immunization schedule except 23-valent pneumococcal polysaccharide and zoster vaccines are 
covered by the Vaccine Injury Compensation Program. Information on how to file a vaccine injury claim 
is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. Submit questions 
and comments to CDC through www.cdc.gov/cdc-info or by telephone, 800-CDC-INFO (800-232-
4636), in English and Spanish, 8:00am–8:00pm ET, Monday–Friday, excluding holidays.
The following abbreviations are used for vaccines in the adult immunization schedule (in the order of 
their appearance):
IIV inactivated influenza vaccine
RIV recombinant influenza vaccine
Tdap tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
Td tetanus and diphtheria toxoids
MMR measles, mumps, and rubella vaccine
VAR varicella vaccine 
RZV recombinant zoster vaccine
ZVL zoster vaccine live
HPV vaccine human papillomavirus vaccine
PCV13 13-valent pneumococcal conjugate vaccine
PPSV23 23-valent pneumococcal polysaccharide vaccine
HepA hepatitis A vaccine
HepA-HepB hepatitis A vaccine and hepatitis B vaccine
HepB hepatitis B vaccine
MenACWY serogroups A, C, W, and Y meningococcal vaccine
MenB serogroup B meningococcal vaccine
Hib Haemophilus influenzae type b vaccine
1. MMWR Morb Mortal Wkly Rep. 2018;66(5):xx–xx. Available at www.cdc.gov/mmwr/volumes/67/xxxxxxxxxx.
2. Ann Intern Med. 2018;168:xxx–xxx. Available at annals.org/aim/article/doi/10.7326/M17-3439.
3. Clin Infect Dis. 2014;58:e44-100. Available at www.idsociety.org/Templates/Content.aspx?id=32212256011.
4. Kroger et al. Available at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2018
This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.
Vaccine 19–21 years 22–26 years 27–49 years 50–64 years ≥65 years
Influenza1
Tdap2 or Td2
MMR3
VAR4
RZV5 (preferred)
ZVL5
HPV–Female6
HPV–Male6
PCV137 
PPSV237
HepA8
HepB9
MenACWY10
MenB10
Hib11
1 dose annually
1 dose ZVL
2 doses RZV (preferred)
1 dose
1 dose
2 or 3 doses depending on age at series initiation
2 or 3 doses depending on age at series initiation
1 or 2 doses depending on indication (if born in 1957 or later)
1 dose Tdap, then Td booster every 10 yrs
1 or 2 doses depending on indication
2 or 3 doses depending on vaccine
3 doses
2 doses
1 or 2 doses depending on indication, then booster every 5 yrs if risk remains
2 or 3 doses depending on vaccine
1 or 3 doses depending on indication
Recommended for adults who meet the  
age requirement, lack documentation of 
vaccination, or lack evidence of past infection
Recommended for adults with other 
indications No recommendation
or or
Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2018 
This figure should be reviewed with the accompanying footnotes. This figure and the footnotes describe indications for which vaccines, if not previously administered, should be administered unless noted otherwise.
Vaccine Pregnancy1-6
Immuno-
compromised 
(excluding HIV 
infection)3-7,11
HIV infection
CD4+ count 
 (cells/μL)3-7,9-10
Asplenia, 
complement 
deficiencies7,10,11
End-stage renal 
disease, on 
hemodialysis7,9
Heart or
lung disease, 
alcoholism7
Chronic liver 
disease7-9 Diabetes7,9
Health care
personnel3,4,9
Men who 
have sex 
with men6,8,9<200 ≥200
Influenza1
Tdap2 or Td2
1 dose 
Tdap each 
pregnancy
MMR3
VAR4
RZV5 (preferred)
ZVL5
HPV–Female6 3 doses through age 26 yrs
HPV–Male6
2 or 3 doses  
through age 
26 yrs
PCV137 
PPSV237
HepA8
HepB9
MenACWY10
MenB10
Hib11 3 doses HSCT  recipients only
Recommended for adults who meet the  
age requirement, lack documentation of 
vaccination, or lack evidence of past infection
Recommended for adults with other 
indications Contraindicated No recommendation
3 doses
2 or 3 doses depending on vaccine
1 dose
1 dose
1, 2, or 3 doses depending on indication
2 or 3 doses depending on vaccine
1 or 2 doses depending on indication , then booster every 5 yrs if risk remains
2 doses RZV at age >50 yrs (preferred)
contraindicated
contraindicated
1 or 2 doses depending on indication
2 or 3 doses through age 26 yrs
2 doses
3 doses through age 26 yrs
1 dose annually
1 dose Tdap, then Td booster every 10 yrs
2 or 3 doses through age 21 yrs
1 dose ZVL at age >60 yrscontraindicated
or or
Footnotes. Recommended immunization schedule for adults aged 19 years or older, United States, 2018
1. Influenza vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html
General information
• Administer 1 dose of age-appropriate inactivated influenza 
vaccine (IIV) or recombinant influenza vaccine (RIV) annually
• Live attenuated influenza vaccine (LAIV) is not recommended 
for the 2017–2018 influenza season
• A list of currently available influenza vaccines is available at  
www.cdc.gov/flu/protect/vaccine/vaccines.htm
Special populations
• Administer age-appropriate IIV or RIV to: 
 ʱ Pregnant women
 ʱ Adults with hives-only egg allergy
 ʱ Adults with egg allergy other than hives (e.g., 
angioedema or respiratory distress): Administer IIV or RIV 
in a medical setting under supervision of a health care 
provider who can recognize and manage severe allergic 
conditions
2. Tetanus, diphtheria, and pertussis vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html 
General information
• Administer to adults who previously did not receive a dose 
of tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine (Tdap) as an adult or child (routinely 
recommended at age 11–12 years) 1 dose of Tdap, followed 
by a dose of tetanus and diphtheria toxoids (Td) booster 
every 10 years
• Information on the use of Tdap or Td as tetanus prophylaxis 
in wound management is available at www.cdc.gov/mmwr/
preview/mmwrhtml/rr5517a1.htm
Special populations
• Pregnant women: Administer 1 dose of Tdap during each 
pregnancy, preferably in the early part of gestational weeks 
27–36
3. Measles, mumps, and rubella vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html 
General information
• Administer 1 dose of measles, mumps, and rubella vaccine 
(MMR) to adults with no evidence of immunity to measles, 
mumps, or rubella
• Evidence of immunity is:
 ʱ Born before 1957 (except for health care personnel, see 
below)
 ʱ Documentation of receipt of MMR
 ʱ Laboratory evidence of immunity or disease
• Documentation of a health care provider-diagnosed disease 
without laboratory confirmation is not considered evidence 
of immunity
Special populations
• Pregnant women and nonpregnant women of 
childbearing age with no evidence of immunity to rubella: 
Administer 1 dose of MMR (if pregnant, administer MMR after 
pregnancy and before discharge from health care facility)
• HIV infection and CD4 cell count ≥200 cells/μL for at least 
6 months and no evidence of immunity to measles, mumps, 
or rubella: Administer 2 doses of MMR at least 28 days apart 
• Students in postsecondary educational institutions, 
international travelers, and household contacts of 
immunocompromised persons: Administer 2 doses of 
MMR at least 28 days apart (or 1 dose of MMR if previously 
administered 1 dose of MMR)
• Health care personnel born in 1957 or later with no 
evidence of immunity: Administer 2 doses of MMR at least 
28 days apart for measles or mumps, or 1 dose of MMR for 
rubella (if born before 1957, consider MMR vaccination)
• Adults who previously received ≤2 doses of mumps-
containing vaccine and are identified by public health 
authority to be at increased risk for mumps in an 
outbreak: Administer 1 dose of MMR
• MMR is contraindicated for pregnant women and adults with 
severe immunodeficiency
4. Varicella vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html 
General information
• Administer to adults without evidence of immunity to 
varicella 2 doses of varicella vaccine (VAR) 4–8 weeks apart 
if previously received no varicella-containing vaccine (if 
previously received 1 dose of varicella-containing vaccine, 
administer 1 dose of VAR at least 4 weeks after the first dose)  
• Evidence of immunity to varicella is:
 ʱ U.S.-born before 1980 (except for pregnant women and 
health care personnel, see below)
 ʱ Documentation of receipt of 2 doses of varicella or 
varicella-containing vaccine at least 4 weeks apart
 ʱ Diagnosis or verification of history of varicella or herpes 
zoster by a health care provider
 ʱ Laboratory evidence of immunity or disease
Special populations
• Administer 2 doses of VAR 4–8 weeks apart if previously 
received no varicella-containing vaccine (if previously 
received 1 dose of varicella-containing vaccine, administer 1 
dose of VAR at least 4 weeks after the first dose) to:
 ʱ Pregnant women without evidence of immunity: 
Administer the first of the 2 doses or the second dose after 
pregnancy and before discharge from health care facility
 ʱ Health care personnel without evidence of immunity
• Adults with HIV infection and CD4 cell count ≥200 cells/μL: 
May administer, based on individual clinical decision, 2 doses 
of VAR 3 months apart
• VAR is contraindicated for pregnant women and adults with 
severe immunodeficiency
5. Zoster vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html
General information
• Administer 2 doses of recombinant zoster vaccine (RZV) 2–6 
months apart to adults aged 50 years or older regardless of 
past episode of herpes zoster or receipt of zoster vaccine live 
(ZVL)
• Administer 2 doses of RZV 2–6 months apart to adults who 
previously received ZVL at least 2 months after ZVL
• For adults aged 60 years or older, administer either RZV or 
ZVL (RZV is preferred)
Special populations
• ZVL is contraindicated for pregnant women and adults with 
severe immunodeficiency
6. Human papillomavirus vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html 
General information
• Administer human papillomavirus (HPV) vaccine to females 
through age 26 years and males through age 21 years 
(males aged 22 through 26 years may be vaccinated based 
on individual clinical decision)  
• The number of doses of HPV vaccine to be administered 
depends on age at initial HPV vaccination
 ʱ No previous dose of HPV vaccine: Administer 3-dose 
series at 0, 1–2, and 6 months (minimum intervals: 4 weeks 
between doses 1 and 2, 12 weeks between doses 2 and 3, 
and 5 months between doses 1 and 3; repeat doses if given 
too soon)
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 1 dose or 2 doses less than 5 months apart: 
Administer 1 dose
 ʱ Aged 9–14 years at HPV vaccine series initiation and 
received 2 doses at least 5 months apart: No additional 
dose is needed
Special populations
• Adults with immunocompromising conditions (including 
HIV infection) through age 26 years: Administer 3-dose 
series at 0, 1–2, and 6 months
• Men who have sex with men through age 26 years: 
Administer 2- or 3-dose series depending on age at initial 
vaccination (see above); if no history of HPV vaccine, 
administer 3-dose series at 0, 1–2, and 6 months
• Pregnant women through age 26 years: HPV vaccination 
is not recommended during pregnancy, but there is no 
evidence that the vaccine is harmful and no intervention 
needed for women who inadvertently receive HPV vaccine 
while pregnant; delay remaining doses until after pregnancy; 
pregnancy testing is not needed before vaccination
7. Pneumococcal vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html 
General information
• Administer to immunocompetent adults aged 65 years or 
older 1 dose of 13-valent pneumococcal conjugate vaccine 
(PCV13), if not previously administered, followed by 1 
dose of 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) at least 1 year after PCV13; if PPSV23 was previously 
administered but not PCV13, administer PCV13 at least 1 year 
after PPSV23
• When both PCV13 and PPSV23 are indicated, administer 
PCV13 first (PCV13 and PPSV23 should not be administered 
during the same visit); additional information on vaccine 
timing is available at www.cdc.gov/vaccines/vpd/pneumo/
downloads/pneumo-vaccine-timing.pdf
Special populations
• Administer to adults aged 19 through 64 years with the 
following chronic conditions 1 dose of PPSV23 (at age 65 
years or older, administer 1 dose of PCV13, if not previously 
received, and another dose of PPSV23 at least 1 year after 
PCV13 and at least 5 years after PPSV23):
 ʱ Chronic heart disease (excluding hypertension)
 ʱ Chronic lung disease
 ʱ Chronic liver disease
 ʱ Alcoholism
 ʱ Diabetes mellitus
 ʱ Cigarette smoking
• Administer to adults aged 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13, and a second dose of 
PPSV23 at least 5 years after the first dose of PPSV23 (if the 
most recent dose of PPSV23 was administered before age 65 
years, at age 65 years or older, administer another dose of 
PPSV23 at least 5 years after the last dose of PPSV23):
 ʱ Immunodeficiency disorders (including B- and 
T-lymphocyte deficiency, complement deficiencies, and 
phagocytic disorders)
 ʱ HIV infection
 ʱ Anatomical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies) 
 ʱ Chronic renal failure and nephrotic syndrome
• Administer to adults aged 19 years or older with the 
following indications 1 dose of PCV13 followed by 1 dose of 
PPSV23 at least 8 weeks after PCV13 (if the dose of PPSV23 
was administered before age 65 years, at age 65 years or 
older, administer another dose of PPSV23 at least 5 years 
after the last dose of PPSV23):
 ʱ Cerebrospinal fluid leak
 ʱ Cochlear implant
8. Hepatitis A vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html 
General information
• Administer to adults who have a specific risk (see below), 
or lack a risk factor but want protection, 2-dose series of 
single antigen hepatitis A vaccine (HepA; Havrix at 0 and 
6–12 months or Vaqta at 0 and 6–18 months; minimum 
interval: 6 months) or a 3-dose series of combined hepatitis 
A and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months; 
minimum intervals: 4 weeks between first and second doses, 
5 months between second and third doses
Special populations
• Administer HepA or HepA-HepB to adults with the following 
indications:
 ʱ Travel to or work in countries with high or intermediate 
hepatitis A endemicity 
 ʱ Men who have sex with men
 ʱ Injection or noninjection drug use
 ʱ Work with hepatitis A virus in a research laboratory 
or with nonhuman primates infected with hepatitis A 
virus
 ʱ Clotting factor disorders
 ʱ Chronic liver disease
 ʱ Close, personal contact with an international adoptee 
(e.g., household or regular babysitting) during the first 60 
days after arrival in the United States from a country with 
high or intermediate endemicity (administer the first dose 
as soon as the adoption is planned)
 ʱ Healthy adults through age 40 years who have recently 
been exposed to hepatitis A virus; adults older than age 
40 years may receive HepA or HepA-HepB if hepatitis A 
immunoglobulin cannot be obtained
9. Hepatitis B vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html 
General information
• Administer to adults who have a specific risk (see below), or 
lack a risk factor but want protection, 3-dose series of single 
antigen hepatitis B vaccine (HepB) or combined hepatitis A 
and hepatitis B vaccine (HepA-HepB) at 0, 1, and 6 months 
(minimum intervals: 4 weeks between doses 1 and 2 for 
HepB and HepA-HepB; between doses 2 and 3, 8 weeks for 
HepB and 5 months for HepA-HepB)
Special populations
• Administer HepB or HepA-HepB to adults with the following 
indications:
 ʱ Chronic liver disease (e.g., hepatitis C infection, cirrhosis, 
fatty liver disease, alcoholic liver disease, autoimmune 
hepatitis, alanine aminotransferase [ALT] or aspartate 
aminotransferase [AST] level greater than twice the upper 
limit of normal)
 ʱ HIV infection
 ʱ Percutaneous or mucosal risk of exposure to blood 
(e.g., household contacts of hepatitis B surface antigen 
[HBsAg]-positive persons; adults younger than age 60 
years with diabetes mellitus or aged 60 years or older 
with diabetes mellitus based on individual clinical decision; 
adults in predialysis care or receiving hemodialysis or 
peritoneal dialysis; recent or current injection drug 
users; health care and public safety workers at risk for 
exposure to blood or blood-contaminated body fluids)
 ʱ Sexual exposure risk (e.g., sex partners of HBsAg-
positive persons; sexually active persons not in a mutually 
monogamous relationship; persons seeking evaluation or 
treatment for a sexually transmitted infection; and men 
who have sex with men [MSM])
 ʱ Receive care in settings where a high proportion of 
adults have risks for hepatitis B infection (e.g., facilities 
providing sexually transmitted disease treatment, drug-
abuse treatment and prevention services, hemodialysis 
and end-stage renal disease programs, institutions for 
developmentally disabled persons, health care settings 
targeting services to injection drug users or MSM, HIV 
testing and treatment facilities, and correctional facilities)
 ʱ Travel to countries with high or intermediate hepatitis B 
endemicity
10. Meningococcal vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html 
Special populations: Serogroups A, C, W, and Y 
meningococcal vaccine (MenACWY)
• Administer 2 doses of MenACWY at least 8 weeks apart and 
revaccinate with 1 dose of MenACWY every 5 years, if the risk 
remains, to adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease and other hemoglobinopathies)
 ʱ HIV infection
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
• Administer 1 dose of MenACWY and revaccinate with 1 dose 
of MenACWY every 5 years, if the risk remains, to adults with 
the following indications:
 ʱ Travel to or live in countries where meningococcal 
disease is hyperendemic or epidemic, including 
countries in the African meningitis belt or during the Hajj
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup A, C, W, or Y
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
 ʱ Military recruits
 ʱ First-year college students who live in residential 
housing (if they did not receive MenACWY at age 16 years 
or older)
General Information: Serogroup B meningococcal vaccine 
(MenB)
 ʱ May administer, based on individual clinical decision, to 
young adults and adolescents aged 16–23 years (preferred 
age is 16–18 years) who are not at increased risk 2-dose 
series of MenB-4C (Bexsero) at least 1 month apart or 
2-dose series of MenB-FHbp (Trumenba) at least 6 months 
apart
 ʱ MenB-4C and MenB-FHbp are not interchangeable
Special populations: MenB
• Administer 2-dose series of MenB-4C at least 1 month apart 
or 3-dose series of MenB-FHbp at 0, 1–2, and 6 months to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease)
 ʱ Persistent complement component deficiency
 ʱ Eculizumab use
 ʱ At risk from a meningococcal disease outbreak 
attributed to serogroup B
 ʱ Microbiologists routinely exposed to Neisseria 
meningitidis
11.  Haemophilus influenzae type b vaccination
www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html 
Special populations
• Administer Haemophilus influenzae type b vaccine (Hib) to 
adults with the following indications:
 ʱ Anatomical or functional asplenia (including sickle cell 
disease) or undergoing elective splenectomy: Administer 
1 dose  if not previously vaccinated (preferably at least 14 
days before elective splenectomy)
 ʱ Hematopoietic stem cell transplant (HSCT): Administer 
3-dose series with doses 4 weeks apart starting 6 to 12 
months after successful transplant regardless of Hib 
vaccination history
Vaccine(s) Additional Contraindications Additional Precautions
IIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
• Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent 
emesis; or required epinephrine or another emergency medical intervention (IIV may be 
administered in an inpatient or outpatient medical setting and under the supervision of a health 
care provider who is able to recognize and manage severe allergic conditions)
RIV1 • History of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination
Tdap, Td • For pertussis-containing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, 
or prolonged seizures, not attributable to another identifiable cause within 7 days of 
administration of a previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular 
pertussis
• Guillain-Barré syndrome within 6 weeks after a previous dose of tetanus toxoid-containing 
vaccine
• History of Arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria 
toxoid-containing vaccine. Defer vaccination until at least 10 years have elapsed since the last 
tetanus toxoid-containing vaccine
• For pertussis-containing vaccine, progressive or unstable neurologic disorder, uncontrolled 
seizures, or progressive encephalopathy (until a treatment regimen has been established and the 
condition has stabilized)
MMR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, human immunodeficiency virus 
(HIV) infection with severe immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• History of thrombocytopenia or thrombocytopenic purpura
• Need for tuberculin skin testing5
VAR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval 
depends on product)4
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
ZVL2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before 
vaccination (avoid use of these antiviral drugs for 14 days after vaccination)
HPV vaccine • Pregnancy
PCV13 • Severe allergic reaction to any vaccine containing diphtheria toxoid
1. For additional information on use of influenza vaccines among persons with egg allergy, see: CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization 
Practices—United States, 2016–17 influenza season. MMWR. 2016;65(RR-5):1–54. Available at www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm.
2. MMR may be administered together with VAR or ZVL on the same day. If not administered on the same day, separate live vaccines by at least 28 days. 
3. Immunosuppressive steroid dose is considered to be daily receipt of 20 mg or more prednisone or equivalent for 2 or more weeks. Vaccination should be deferred for at least 1 month after discontinuation of 
immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines among persons on immune-suppressing medications or with immune 
suppression because of other reasons.
4. Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered. See: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at 
www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. 
5. Measles vaccination may temporarily suppress tuberculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.
Table. Contraindications and precautions for vaccines recommended for adults aged 19 years or older*
The Advisory Committee on Immunization Practices (ACIP) recommendations and package inserts for vaccines provide information on contraindications and precautions related to vaccines. Contraindications are conditions 
that increase chances of a serious adverse reaction in vaccine recipients and the vaccine should not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine 
recipients. 
Vaccine(s) Contraindications Precautions
All vaccines routinely 
recommended for adults
• Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component • Moderate or severe acute illness with or without fever
Additional contraindications and precautions for vaccines routinely recommended for adults
Contraindications and precautions for vaccines routinely recommended for adults
*  Adapted from: CDC. Table 6. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. 
2011;60(No. RR-2):40–1 and from: Hamborsky J, Kroger A, Wolfe S, eds. Appendix A. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington, DC: Public Health Foundation, 2015. Available at www.cdc.
gov/vaccines/pubs/pinkbook/index.html. 
Abbreviations of vaccines
IIV inactivated influenza vaccine
RIV recombinant influenza vaccine
Tdap  tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis vaccine
Td  tetanus and diphtheria toxoids
MMR  measles, mumps, and rubella vaccine
VAR varicella vaccine
RZV recombinant zoster vaccine
ZVL zoster vaccine live
HPV vaccine human papillomavirus vaccine
PCV13  13-valent pneumococcal conjugate vaccine 
PPSV23  23-valent pneumococcal polysaccharide vaccine
HepA hepatitis A vaccine
HepA-HepB hepatitis A and hepatitis B vaccines
HepB hepatitis B vaccine
MenACWY serogroups A, C, W, and Y meningococcal vaccine
MenB  serogroup B meningococcal vaccine
Hib  Haemophilus influenzae type b vaccine
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